Protalix BioTherapeutics (PLX) Competitors $1.81 +0.03 (+1.69%) (As of 10:34 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends PLX vs. MREO, CRMD, XERS, VERV, PROK, TERN, KOD, RNAC, PHAT, and PRTCShould you be buying Protalix BioTherapeutics stock or one of its competitors? The main competitors of Protalix BioTherapeutics include Mereo BioPharma Group (MREO), CorMedix (CRMD), Xeris Biopharma (XERS), Verve Therapeutics (VERV), ProKidney (PROK), Terns Pharmaceuticals (TERN), Kodiak Sciences (KOD), Cartesian Therapeutics (RNAC), Phathom Pharmaceuticals (PHAT), and PureTech Health (PRTC). These companies are all part of the "pharmaceutical products" industry. Protalix BioTherapeutics vs. Mereo BioPharma Group CorMedix Xeris Biopharma Verve Therapeutics ProKidney Terns Pharmaceuticals Kodiak Sciences Cartesian Therapeutics Phathom Pharmaceuticals PureTech Health Mereo BioPharma Group (NASDAQ:MREO) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, community ranking, dividends, profitability, valuation, media sentiment and analyst recommendations. Is MREO or PLX more profitable? Mereo BioPharma Group has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Mereo BioPharma Group's return on equity of 0.00% beat Protalix BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mereo BioPharma GroupN/A N/A N/A Protalix BioTherapeutics -21.03%-30.89%-11.74% Do institutionals & insiders have more ownership in MREO or PLX? 62.8% of Mereo BioPharma Group shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 4.1% of Mereo BioPharma Group shares are owned by insiders. Comparatively, 6.3% of Protalix BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in MREO or PLX? Mereo BioPharma Group received 41 more outperform votes than Protalix BioTherapeutics when rated by MarketBeat users. Likewise, 78.69% of users gave Mereo BioPharma Group an outperform vote while only 70.00% of users gave Protalix BioTherapeutics an outperform vote. CompanyUnderperformOutperformMereo BioPharma GroupOutperform Votes4878.69% Underperform Votes1321.31% Protalix BioTherapeuticsOutperform Votes770.00% Underperform Votes330.00% Which has higher earnings & valuation, MREO or PLX? Protalix BioTherapeutics has higher revenue and earnings than Mereo BioPharma Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMereo BioPharma Group$1M591.11-$29.47MN/AN/AProtalix BioTherapeutics$45.67M2.87$8.31M-$0.13-13.69 Does the media prefer MREO or PLX? In the previous week, Mereo BioPharma Group had 7 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 8 mentions for Mereo BioPharma Group and 1 mentions for Protalix BioTherapeutics. Mereo BioPharma Group's average media sentiment score of 0.54 beat Protalix BioTherapeutics' score of 0.00 indicating that Mereo BioPharma Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mereo BioPharma Group 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend MREO or PLX? Mereo BioPharma Group presently has a consensus target price of $7.83, indicating a potential upside of 105.60%. Given Mereo BioPharma Group's stronger consensus rating and higher probable upside, equities research analysts plainly believe Mereo BioPharma Group is more favorable than Protalix BioTherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mereo BioPharma Group 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.43Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryMereo BioPharma Group beats Protalix BioTherapeutics on 13 of the 16 factors compared between the two stocks. Ad StocksToTradeliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the liberals broke”... But it turns out that was all just a smokescreen to hide the TRUTH…Click here to discover the real reason Elon Musk became buddy-buddy with Trump. Get Protalix BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLX vs. The Competition Export to ExcelMetricProtalix BioTherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$131.07M$2.96B$5.24B$19.39BDividend YieldN/A1.91%5.12%3.64%P/E Ratio-13.6945.6887.3841.47Price / Sales2.87420.871,164.3318.16Price / Cash13.19174.7643.3821.28Price / Book3.793.924.845.36Net Income$8.31M-$42.00M$121.05M$990.70M7 Day Performance2.30%2.90%2.49%2.13%1 Month Performance5.95%-1.69%17.57%-4.23%1 Year Performance-2.73%15.34%28.57%11.46% Protalix BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLXProtalix BioTherapeuticsN/A$1.81+1.7%N/A-1.1%$133.28M$45.67M-13.92200News CoverageMREOMereo BioPharma Group2.215 of 5 stars$3.33-0.6%$7.40+122.2%+78.9%$516.64M$1M0.0040Analyst UpgradeNews CoverageCRMDCorMedix1.891 of 5 stars$8.39-2.1%$15.80+88.3%+122.1%$509.08M$12.26M-10.3630XERSXeris Biopharma3.7663 of 5 stars$3.37-3.4%$4.87+44.4%+66.0%$502.40M$187.36M-7.49290VERVVerve Therapeutics2.7 of 5 stars$5.92+3.1%$25.75+335.0%-59.6%$501.21M$24.40M-2.41110PROKProKidney1.8973 of 5 stars$1.70+12.3%$4.50+165.5%-12.3%$494.37MN/A-3.083TERNTerns Pharmaceuticals4.2968 of 5 stars$5.82-0.7%$18.30+214.4%-11.6%$494.35M$1M-4.9340Positive NewsKODKodiak Sciences2.7661 of 5 stars$9.30+7.5%$8.00-14.0%+224.7%$489.40MN/A-2.5590Gap UpRNACCartesian Therapeutics2.5715 of 5 stars$19.21+1.0%$42.86+123.1%-13.8%$488.22M$47.94M-0.3637Gap UpPHATPhathom Pharmaceuticals2.8262 of 5 stars$7.13-4.3%$23.00+222.6%-16.8%$487.53M$26.27M-1.25110PRTCPureTech Health2.0723 of 5 stars$20.01-1.4%$45.00+124.9%-21.9%$479.08M$3.33M0.00100Gap Down Related Companies and Tools Related Companies Mereo BioPharma Group Alternatives CorMedix Alternatives Xeris Biopharma Alternatives Verve Therapeutics Alternatives ProKidney Alternatives Terns Pharmaceuticals Alternatives Kodiak Sciences Alternatives Cartesian Therapeutics Alternatives Phathom Pharmaceuticals Alternatives PureTech Health Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:PLX) was last updated on 12/26/2024 by MarketBeat.com Staff From Our Partnersliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored“AI Killer” 10x More Powerful Than ChatGPTElon Musk may be about to “kill” the world’s most powerful AI. Very few people are talking about the one AI...Paradigm Press | SponsoredThere’s One Thing Trump and Musk Can’t FixDonald Trump and Elon Musk are teaming up to fix America's broken government. With the launch of the Depart...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
